ESMO Media Releases

Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial to be presented at ELCC

Patients with advanced non-small-cell lung cancer (NSCLC) who require salvage chemotherapy are 30% more likely to achieve a partial response if they have been pre-treated with a PD-1/PD-L1 checkpoint inhibitor compared to those who have not

Research to be presented at the European Lung Cancer Conference in Geneva, Switzerland on Saturday

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the drugs.

Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect

ESMO and IASLC have announced that the 2017 Heine H. Hansen (HHH) Award will be given to Rafal Dziadziuszko, a global leader in clinical thoracic oncology

ESMO and IASLC are pleased to invite journalists to a media brief taking place at the beginning of the European Lung Cancer Conference (ELCC) in the Palexpo Centre in Geneva, on Friday 5 May 2017, from 12:00 to 12:45 CEST

Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the field of thoracic oncology at the seventh European Lung Cancer Conference (ELCC) in Geneva, Switzerland, from 5 to 8 May 2017

ESMO has announced it will take over the organisation of the Targeted Anticancer Therapies (TAT) Congress series, with the aim of expanding its educational offer and ensure that professionals are kept up to date with the latest drug developments to improve outcomes for cancer patients

Save the dates and join us at the many events ESMO is hosting in 2017. ESMO meetings are the place to be, to keep up to date with the latest news in oncology.

Death rates from cancer in the European Union (EU) are falling faster in men than in women, according to the latest predictions for European cancer deaths in 2017, published in the leading cancer journal Annals of Oncology

ESMO presented an official statement supporting the 2017 WHO Cancer Resolution that was discussed at the 140th session of the WHO Executive Board meeting in Geneva, 23-31 January 2017